The Landscape of the Advanced NSCLC Treatment Paradigm: Molecular Testing and Actionable Mutations
Presented by Rasheda Persinger, AGNP-C
From Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center at Sibley Memorial Hospital, Baltimore, Maryland
J Adv Pract Oncol 2021;12(3):301–305 |
© 2021 Harborside™
At JADPRO Live Virtual 2020, Rasheda Persinger, AGNP-C, explained the current lung cancer treatment landscape, including targeted therapies for EGFR and ALK rearrangements, as well as for BRAF, ROS1, NTRK, RET, MET, and KRAS mutations, and described the different testing modalities for molecular markers.
For access to the full length article, please sign in